This week marks a century since the first description of Alzheimer's disease (AD). Despite
approval of several drugs for AD, the disease continues to rob millions of their memories and …

Identifying the systems-level mechanisms that lead to Alzheimer's disease, an unmet need,
is an essential step toward the development of therapeutics. In this work, we report that the …

Alzheimer's disease (AD) is a progressive, neurodegenerative dementia with no cure.
Prominent hypotheses suggest accumulation of beta-amyloid (Aβ) contributes to …

Despite expressing many key risk genes, the role of microglia in late-onset Alzheimer's
disease pathophysiology is somewhat ambiguous, with various phenotypes reported to be …

Amyloid: Little proteins, big clues | Nature Skip to main content Thank you for visiting nature.com.
You are using a browser version with limited support for CSS. To obtain the best experience …

The pathological hallmarks of Alzheimer′ s disease (AD)—widespread synaptic and
neuronal loss and the pathological accumulation of amyloid‐beta peptide (Aβ) in senile …

Alzheimer's disease (AD) is accompanied by a robust inflammatory response mediated by
plaque-associated myeloid cells of the brain. These cells exhibit altered gene expression …

Several genetic risk factors for Alzheimer's disease implicate genes involved in lipid
metabolism and many of these lipid genes are highly expressed in glial cells. However, the …

The APOE4 allele is the strongest genetic risk factor for late-onset Alzheimer's disease (AD).
The contribution of microglial APOE4 to AD pathogenesis is unknown, although APOE has …

Microglial cells closely interact with senile plaques in Alzheimer's disease and acquire the
morphological appearance of an activated phenotype. The significance of this microglial …